The health and care system across the United Kingdom is taking action against the growing threat of infections that are resistant to the antimicrobial drugs used to treat them.<\/p>
<\/p>
<\/p>
<\/p>
In December 2014, we published the UK Five Year AMR Strategy detailed implementation plan. The plan set out those activities that needed to be undertaken to deliver the strategy in each of seven key areas for action. Activity in the plan is led by the Department of Health, Public Health England, Department for Environment, Food and Rural Affairs and NHS England and is incorporated within existing business plans for those organisations.<\/p>
<\/p>
<\/p>
<\/p>
The Government has no current plans to make additional funding available to tackle drug-resistant infections. Any proposals for funding would be subject to the outcome of the Spending Review later this year.<\/p>
<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-08T10:54:59.777Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Antimicrobials: Drug Resistance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what plans his Department has to make additional funding available to tackle drug-resistant infections over the next five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"} ], "uin" : "1028"} , {"_about" : "http://data.parliament.uk/resources/348258", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/348258/answer", "answerText" : {"_value" : "
Public Health England (PHE) has published no estimates for the number of drug-resistant infections in the West Midlands or nationally over the next five years. The science of drug resistant infections is incompletely understood and is rapidly changing and evolving. Multi-drug resistant infections are unpredictable in their occurrence and can rapidly change. For these reasons producing estimates of the likely burden in future years is unlikely to be meaningful or robust.<\/p>
<\/p>
<\/p>
<\/p>
Antimicrobial resistance is a priority for PHE who are working to improve surveillance and knowledge in this area. Specific antimicrobial resistant infections have been measured by PHE and openly published in weekly Health Protection Reports.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-08T10:58:32.737Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Infectious Diseases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the number of drug-resistant infections (a) in the West Midlands and (b) nationally in the next five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"} ], "uin" : "1029"} , {"_about" : "http://data.parliament.uk/resources/348273", "AnsweringBody" : [{"_value" : "Ministry of Justice"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/348273/answer", "answerText" : {"_value" : "
We will publish draft clauses in due course.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "answeringMemberConstituency" : {"_value" : "Hemel Hempstead"} , "answeringMemberPrinted" : {"_value" : "Mike Penning"} , "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-08T11:36:40.513Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "54"} , "answeringDeptShortName" : {"_value" : "Justice"} , "answeringDeptSortName" : {"_value" : "Justice"} , "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Crime: Victims"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Justice, when he plans to publish legislative proposals to increase the rights of victims of crime.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4243", "label" : {"_value" : "Biography information for Dan Jarvis"} } , "tablingMemberConstituency" : {"_value" : "Barnsley Central"} , "tablingMemberPrinted" : [{"_value" : "Dan Jarvis"} ], "uin" : "1067"} , {"_about" : "http://data.parliament.uk/resources/348276", "AnsweringBody" : [{"_value" : "Department for Energy and Climate Change"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/348276/answer", "answerText" : {"_value" : "
We are driving forward plans to deliver our manifesto pledge to end new subsidies for onshore wind and to give local communities the final say on windfarm applications as soon as possible. We will publish our plans and timetable for these changes shortly.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-08T09:58:46.297Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "63"} , "answeringDeptShortName" : {"_value" : "Energy and Climate Change"} , "answeringDeptSortName" : {"_value" : "Energy and Climate Change"} , "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Wind Power"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Energy and Climate Change, if she will take steps to reduce the subsidies available to the promotion and construction of on-shore wind farms; and if she will bring forward proposals to ensure that local planning controls over such projects involve adequate consultation with local residents before consent is granted.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/87", "label" : {"_value" : "Biography information for Sir Roger Gale"} } , "tablingMemberConstituency" : {"_value" : "North Thanet"} , "tablingMemberPrinted" : [{"_value" : "Sir Roger Gale"} ], "uin" : "954"} , {"_about" : "http://data.parliament.uk/resources/348397", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/348397/answer", "answerText" : {"_value" : "
Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department\u2019s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.<\/p>
<\/p>
Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom\u2018s leading charity for the condition. More information can be found at the following link:<\/p>
<\/p>
<\/p> <\/p> <\/p> <\/p> www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "963"}
, {"_value" : "964"}
, {"_value" : "965"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-08T10:53:58.267Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hidradenitis Suppurativa: Health Education"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of hidradenitis suppurativa.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
}
, "tablingMemberConstituency" : {"_value" : "West Lancashire"}
, "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
], "uin" : "962"}
, {"_about" : "http://data.parliament.uk/resources/348398", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/348398/answer", "answerText" : {"_value" : " Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department\u2019s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/p> www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "962"}
, {"_value" : "964"}
, {"_value" : "965"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-08T10:54:00.79Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hidradenitis Suppurativa"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
}
, "tablingMemberConstituency" : {"_value" : "West Lancashire"}
, "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
], "uin" : "963"}
, {"_about" : "http://data.parliament.uk/resources/348399", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/348399/answer", "answerText" : {"_value" : " Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department\u2019s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/p> www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "962"}
, {"_value" : "963"}
, {"_value" : "965"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-08T10:54:00.96Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hidradenitis Suppurativa: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
}
, "tablingMemberConstituency" : {"_value" : "West Lancashire"}
, "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
], "uin" : "964"}
, {"_about" : "http://data.parliament.uk/resources/348400", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/348400/answer", "answerText" : {"_value" : " Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department\u2019s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/p>
www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx<\/a><\/p>
In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found at the following link:<\/p>
Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom\u2018s leading charity for the condition. More information can be found at the following link:<\/p>
www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx<\/a><\/p>
In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found at the following link:<\/p>
Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom\u2018s leading charity for the condition. More information can be found at the following link:<\/p>
www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx<\/a><\/p>
In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found at the following link:<\/p>
Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom\u2018s leading charity for the condition. More information can be found at the following link:<\/p>
www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx<\/a><\/p>
In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found at the following link:<\/p>